Partial Response to PPI treatment: The Cost to Society and the Burden to the Patient - a study in France - REMAIN
Study identifier:D9120N00013
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Partial Response to PPI treatment: The Cost to Society and the Burden to the Patient
Medical condition
Gastroesophageal Reflux Disease
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
275
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Feb 2009
Primary Completion Date: 01 Nov 2010
Study Completion Date: 01 Nov 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
i3 Innovus
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 274 GERD patients, partial responders to PPI treatment | - |
Contacts
Investigators
Principal Investigator
Pr Stanislas Bruley des Varannes
Institut des Maladies de l'Appareil Digestif
